Skip to main content
VCbacked
Log inGet Started

Newleos Therapeutics

Boston, United States

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

$93.5M raised
Feb 2025
Series A
BiotechnologyNeuroscience

Top Investors

Novo HoldingsDCVC BioLongwood FundGoldman Sachs AlternativesArkin Bio Ventures

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Newleos Therapeutics

How much funding has Newleos Therapeutics raised?
Newleos Therapeutics has raised $93.5M in total funding. The most recent round was Series A. The last funding was announced in February 2025.
Who are Newleos Therapeutics's investors?
Newleos Therapeutics's investors include Novo Holdings, DCVC Bio, Longwood Fund, Goldman Sachs Alternatives, Arkin Bio Ventures.
Where is Newleos Therapeutics headquartered?
Newleos Therapeutics is headquartered in Boston, United States.
What does Newleos Therapeutics do?
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
What stage is Newleos Therapeutics at?
Newleos Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Newleos Therapeutics — Funding & Investors." VCBacked, February 13, 2025, https://www.vcbacked.co/company/newleos-therapeutics. Accessed June 3, 2026.
APA
VCBacked. (2025). Newleos Therapeutics — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/newleos-therapeutics
Wikipedia (cite web)
{{cite web |title=Newleos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/newleos-therapeutics |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong